Price erosion in US generics
Management acknowledged price erosion on select large products, partially offset by other products. Continued erosion could pressure US margins.
DRREDDY / Q4-FY24 / risks
Keep the risk register visible.
Dr. Reddy's Laboratories · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Forex volatility in emerging markets
Emerging market growth in constant currency may be offset by unfavorable forex movements, particularly in Russia and other markets.
Biosimilar Rituximab CRL delays
US FDA issued a complete response letter for biosimilar Rituximab due to CMC questions; resolution expected around September, but timeline for approval remains uncertain.
Competition in Revlimid generic
Multiple new entrants in the generic Revlimid market could impact pricing and volume, though management declined to discuss specifics.